Barinthus Biotherapeutics PLC
NASDAQ:BRNS

Watchlist Manager
Barinthus Biotherapeutics PLC Logo
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Watchlist
Price: 0.7028 USD -2.56% Market Closed
Market Cap: 28.7m USD

Barinthus Biotherapeutics PLC
Income to Minority Interest

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Barinthus Biotherapeutics PLC
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Income to Minority Interest
$109k
CAGR 3-Years
-24%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Income to Minority Interest
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford BioMedica PLC
LSE:OXB
Income to Minority Interest
ÂŁ2m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Barinthus Biotherapeutics PLC
Glance View

Market Cap
28.7m USD
Industry
Biotechnology

Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

BRNS Intrinsic Value
Not Available

See Also

What is Barinthus Biotherapeutics PLC's Income to Minority Interest?
Income to Minority Interest
109k USD

Based on the financial report for Dec 31, 2024, Barinthus Biotherapeutics PLC's Income to Minority Interest amounts to 109k USD.

What is Barinthus Biotherapeutics PLC's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 5Y
-44%

Over the last year, the Income to Minority Interest growth was 9%. The average annual Income to Minority Interest growth rates for Barinthus Biotherapeutics PLC have been -24% over the past three years , -44% over the past five years .

Back to Top